Navigation Links
Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
Date:12/5/2010

phocytosis may achieve a PR by standard response criteria with continued therapy.

(Photo: http://photos.prnewswire.com/prnh/20101205/SF12271)

Based on the pooled analysis from the Phase Ia study (~8 months median follow-up) and the Ib/II study (<2 months median follow-up) in this group of CLL/SLL patients, of the 45 evaluable patients, one patient achieved a CR (2%), 16 (36%) achieved a PR and an additional 19 (42%) have experienced a dramatic reduction in lymph node disease with lymphocytosis. When evaluating nodal disease alone, 87% percent (34 out of 39) of patients achieved a 50% or greater reduction in lymph node burden.  In patients with symptomatic disease, this early response was often associated with improvement in symptoms.

PCI-32765 continues to be well tolerated in this patient population.  Grade 3/4 events were uncommon. More common grade1/2 events were diarrhea and other GI and constitutional symptoms.  No hepatic or renal laboratory adverse events were reported on this trial and significant hematologic events were infrequent. There was no evidence of cumulative toxicity.

ASH Conference Call and Webcast Details:Date: Wednesday, December 8, 2010Time: 4:30 pm ETSlides used in Presentation: http://ir.pharmacyclics.com/events.cfm Listen via Internet: http://ir.pharmacyclics.com/events.cfm Live Participant Dial In (Toll Free): 877-407-8133 Live Participant Dial In (International): 201-689-8040 To access the live audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com/events.cfm. The archived version of the webcast will be available for 30 days on the Investor Relations section of the company's Web site at www.pha
'/>"/>

SOURCE Pharmacyclics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
2. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
3. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
4. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
5. Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
6. Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7
7. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
8. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
11. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 Amgen (NASDAQ: AMGN ) ... 2014. Key results include: , Total revenues increased ... sales growth driven by strong performance across the portfolio, ... Prolia ® (denosumab) and XGEVA ® (denosumab). ... driven by higher revenues and a significant increase in ...
(Date:7/29/2014)... July 29, 2014 Regado Biosciences, Inc. (Nasdaq: ... the Phase 3 clinical development of Revolixys™ Kit (previously ... system, today announced that it will hold a conference ... 2014, at 8:30 a.m. EDT to discuss its second ... Interested participants and investors may access the conference call ...
(Date:7/29/2014)...  EnteroMedics Inc. (NASDAQ: ETRM ), the ... obesity, metabolic diseases and other gastrointestinal disorders, today announced ... August 7, 2014 at 11:00 AM Eastern Time to ... 30, 2014 and to provide a business update. ... conference call may be accessed by dialing (877) 280-7473 ...
Breaking Medicine Technology:Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3
... 27, 2011 A milestone in lupus research was met this ... Research (ALR) held its 8th annual New York City Walk ... Park was matched by the enthusiasm of the nearly 3000 walkers ... by NYC master of ceremonies, My9 news anchor Brenda Blackmon, ALR ...
... 27, 2011   FHSSA counts its partnership initiative ... known as the Foundation for Hospices in Sub-Saharan ... between US hospice programs and organizations providing care ... assistance, support and friendship.  They are working collaboratively ...
Cached Medicine Technology:Alliance for Lupus NYC Walk With Us to Cure Lupus First Lupus Walk In History To Raise $1-Million 2FHSSA Launches New Campaign to Partner US Hospices with Programs in Sub-Saharan Africa 2
(Date:7/29/2014)... Daily Gossip reveals in its Nasal Polyps Treatment ... he cured his condition with the use of this method ... his experience. , He claimed that he was able ... 4 days. Since his method turned out being so effective, ... the world. , The Nasal Polyps Treatment Miracle program ...
(Date:7/29/2014)... July 29, 2014 Daily Gossip reveals in ... by a holistic nutritional and functional medicine practitioner, who spent ... this problem. , Karen suffered from leaky gut, too, so ... to develop this unique treatment. , Karen Brimeyer decided ... sufferers from all around the world. The author of the ...
(Date:7/29/2014)... 2014 Parker Waichman LLP, a national ... injured by defective drugs and medical devices, reports that ... in Canada who allege that they were never warned ... the low testosterone injection Delatestryl (Court File No. 3704CP/14). ... the Ontario Superior Court of Justice. , “Testosterone lawsuits ...
(Date:7/29/2014)... 2014 Daily Gossip reveals in its review ... system that will permanently eliminate all the symptoms associated to ... treatment will banish symptoms such as mild hearing loss, as ... by patients will be gone forever. , The method will ... author of this program says that at the end of ...
(Date:7/29/2014)... young children to embrace a more healthful diet? ... them. Doing so will actually make them think it ... and caregivers who are struggling to get children to ... food without saying anything about it, or (if credible) ... authors Michal Maimaran, of Northwestern University,s Kellogg School of ...
Breaking Medicine News(10 mins):Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2Health News:Leaky Gut Cure Review Reveals Karen Brimeyer’s Natural Way to Heal Leaky Gut 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2Health News:Kids Will Pass on 'Healthy' Foods 2
... , , WASHINGTON, July 9 The ... the work of the National Organization on Disability,s (N.O.D.) ... emergency managers and the disability community as the only ... and personnel experienced in emergency management and disability issues. ...
... 9 The ongoing recession and associated job cuts ... employee benefit plans, slowing health insurer growth and pressuring ... and Consulting. , , "Conning projects that health ... resulting in deteriorating margins through 2011," said Terence Martin, ...
... Hospital for Special Surgery have shown that a biodegradable scaffold ... knee cartilage. The study is unique in that it used ... to examine how the plug incorporated itself into the knee. ... meeting of the American Orthopedic Society for Sports Medicine, June ...
... ... the world,s leading manufacturer and distributor of automated blood pressure monitors and health testing ... ... 2009 -- Lifeclinic International has named Lon von Hurwitz Executive Vice President ...
... externally , THURSDAY, July 9 (HealthDay News) -- U.S. ... ear infections in children. , Antibiotics are typically used ... for children with recurrent ear infections. , "The emergence ... surgical procedure raise the need to develop different ways ...
... 9 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited (NYSE: ... devices worldwide, today announced that it will report its,financial ... after the U.S.,market closes on August 10, 2009. Mindray,s ... on August 11, 2009 U.S. Eastern Time (8:00 PM ...
Cached Medicine News:Health News:Walmart Foundation Commits $500,000 to Improving Emergency Preparedness for the 54 Million Americans with Disabilities 2Health News:Walmart Foundation Commits $500,000 to Improving Emergency Preparedness for the 54 Million Americans with Disabilities 3Health News:Conning Research: Health Insurance Industry Premium Growth and Profitability Under Pressure Through 2011 2Health News:Study identifies potential fix for damaged knees 2Health News:Study identifies potential fix for damaged knees 3Health News:Pioneer of Digital Place-Based Media Joins World's Leading Blood Pressure and Health Kiosk Manufacturer 2Health News:Vaccine May Someday Thwart Ear Infections 2Health News:Mindray to Report Second Quarter 2009 Financial Results on August 10, 2009 2
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Kleinert-Kutz Single Skin Hook, Large...
Designated most popular model or size....
Medicine Products: